Search & Analyze

Natco Pharma Ltd.

HealthcarePharmaceuticals & Drugs

www.natcopharma.co.in BSE: 524816NSE: NATCOPHARM

₹813.20BSE0.22%

16 Sep, 4:01 PM

₹813.20

₹14.57K Cr

12.73

1.56

16.30%

₹828.30

₹801.00

₹1,217.40

₹789.30

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Natco Pharma Ltd. NATCOPHARM	813.20	12.73	14,565.21	0.61	206.50	-57.01%	735.20	-44.68%	17.16

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	1,068.30	1,362.60	1,371.10	474.80	1,221.00	1,328.90	1,363.00	647.30	739.10	735.20
Expenses	571.00	557.80	566.80	436.00	672.90	757.90	783.80	488.60	611.50	548.70
	497.30	804.80	804.30	38.80	548.10	571.00	579.20	158.70	127.60	186.50
	46.55%	59.06%	58.66%	8.17%	44.89%	42.97%	42.49%	24.52%	17.26%	25.37%
	42.00	48.10	63.80	176.30	66.30	61.70	100.00	58.10	77.80	59.20
Interest	6.20	5.20	4.10	4.40	10.20	3.20	13.10	9.50	10.90	13.00
	55.50	44.10	45.80	47.00	98.30	57.60	52.40	46.20	50.40	47.10
	477.60	803.60	818.20	163.70	505.90	571.90	613.70	172.00	179.80	269.90
	19.12%	16.81%	17.32%	19.12%	19.75%	16.02%	15.61%	12.03%	-49.61%	23.49%
	386.30	668.50	677.30	133.00	406.60	480.70	518.40	151.50	267.90	206.50
	21.58	37.35	37.84	7.43	22.72	26.85	28.96	8.46	14.97	11.54

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	2,216.30	2,881.30	4,331.80	4,763.80	4,698.80
	1,944.80	2,707.10	3,998.80	4,429.50	4,078.30
EXPENDITURE :
Increase/Decrease in Stock	-16.80	-23.70	42.70	-12.50	-106.20
Raw Material Consumed	545.20	606.90	625.20	654.00	721.80
Power & Fuel Cost	76.40	81.90	88.90	93.10	96.90
Employee Cost	444.80	486.70	525.00	594.50	687.20
Other Manufacturing Expenses	353.60	279.60	368.40	374.80	560.50
General and Administration Expenses	152.80	208.80	313.00	304.00	376.20
Selling and Distribution Expenses	43.70	96.10	153.00	136.40	173.20
Miscellaneous Expenses	81.60	59.10	131.20	91.40	132.20
	1,681.30	1,795.40	2,247.40	2,235.70	2,641.80
Operating Profit (Excl OI)	263.50	911.70	1,751.40	2,193.80	1,436.50
	99.00	128.50	128.10	356.70	297.60
	362.50	1,040.20	1,879.50	2,550.50	1,734.10
Interest	17.70	14.50	19.20	23.90	36.70
PBDT	344.80	1,025.70	1,860.30	2,526.60	1,697.40
	142.60	163.80	186.80	235.20	206.60
Profit Before Taxation & Exceptional Items	202.20	861.90	1,673.50	2,291.40	1,490.80
	202.20	861.90	1,673.50	2,291.40	1,490.80
Provision for Tax	32.20	146.60	285.20	408.00	118.90
	170.00	715.30	1,388.30	1,883.40	1,371.90
Extra items				0.00	0.00
Minority Interest				2.00
Share of Associate					46.60
Consolidated Net Profit	170.00	715.30	1,388.30	1,885.40	1,418.50
Profit Balance B/F	2,568.20	2,666.60	3,292.30	4,465.70	6,246.60
Appropriations	2,738.20	3,381.90	4,680.60	6,351.10	7,665.10
Equity Dividend %	225.00%	275.00%	475.00%	300.00%	250.00%
	9.32	39.19	77.56	105.33	79.25
Adjusted EPS	9.32	39.19	77.56	105.33	79.25

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	36.50	36.50	35.80	35.80	35.80
Share Warrants & Outstandings	3.40
Total Reserves	4,223.70	4,837.30	5,817.30	7,571.20	9,185.30
Reserve excluding Revaluation Reserve	4,223.70	4,837.30	5,817.30	7,571.20	9,185.30
Revaluation reserve			0.00
	4,263.60	4,873.80	5,853.10	7,607.00	9,221.10
Minority Interest				5.30
Secured Loans					100.00
Deferred Tax Assets / Liabilities	30.10	12.40	-19.20	-49.90	-232.40
Other Long Term Liabilities	9.30	2.80	9.30	9.20	9.70
Long Term Provisions	95.70	85.30	70.90	65.60	61.80
Total Non-Current Liabilities	135.10	100.50	61.00	24.90	-60.90
Trade Payables	161.80	263.80	235.50	274.90	409.30
Other Current Liabilities	126.70	227.30	238.90	238.60	614.50
Short Term Borrowings	404.00	165.00	363.20	273.10	306.40
Short Term Provisions	17.90	27.00	135.20	156.90	350.70
Total Current Liabilities	710.40	683.10	972.80	943.50	1,680.90
Total Liabilities	5,109.10	5,657.40	6,886.90	8,580.70	10,841.10
Gross Block	3,126.90	3,375.10	3,603.20	4,015.20	4,255.70
Less: Accumulated Depreciation	815.10	948.20	1,112.40	1,267.20	1,403.00
Less: Impairment of Assets				50.00	50.00
Net Block	2,311.80	2,426.90	2,490.80	2,698.00	2,802.70
Capital Work in Progress	129.50	64.30	137.30	225.40	293.70
Non Current Investments	104.40	87.30	95.90	152.80	2,548.90
Long Term Investment	104.40	87.30	95.90	152.80	2,548.90
Long Term Loans & Advances	72.00	78.30	112.70	73.80	100.80
Other Non Current Assets	4.70	0.30	26.70	160.70	42.70
Total Non-Current Assets	2,622.40	2,657.10	2,863.40	3,310.70	5,788.80
Currents Investments	203.70	305.00	443.50	320.80	578.20
Inventories	762.00	742.90	700.50	765.80	908.50
Sundry Debtors	620.60	856.10	1,188.90	1,246.60	881.20
Cash and Bank	206.10	546.30	952.90	2,176.00	1,550.90
Other Current Assets	88.10	64.40	99.50	135.10	102.40
Short Term Loans and Advances	606.20	485.60	638.20	625.70	1,031.10
Total Current Assets	2,486.70	3,000.30	4,023.50	5,270.00	5,052.30
Net Current Assets (Including Current Investments)	1,776.30	2,317.20	3,050.70	4,326.50	3,371.40
Total Assets	5,109.10	5,657.40	6,886.90	8,580.70	10,841.10
Contingent Liabilities	8.00	14.60	0.40	3.00	3.00
Total Debt	404.00	165.00	363.20	273.10	706.40
	233.44	267.06	326.99	424.97	515.15
Adjusted Book Value	233.44	267.06	326.99	424.97	515.15

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	202.20	861.90	1,673.50	2,291.40	1,490.80
Adjustment	123.90	102.00	133.80	-22.30	29.70
Changes In working Capital	-231.40	62.70	-309.40	-199.70	645.50
Cash Flow after changes in Working Capital	94.70	1,026.60	1,497.90	2,069.40	2,166.00
Cash Flow from Operating Activities	46.50	849.10	1,211.60	1,696.80	1,768.30
Cash Flow from Investing Activities	-5.30	-477.10	-1,032.70	-1,414.50	-2,081.70
Cash Flow from Financing Activitie	34.80	-363.00	-246.90	-210.70	297.50
Net Cash Inflow / Outflow	76.00	9.00	-68.00	71.60	-15.90
Opening Cash & Cash Equivalents	25.80	111.10	131.90	70.40	120.00
Effect of Foreign Exchange Fluctuations	9.30	11.80	6.50	-22.00	94.80
Closing Cash & Cash Equivalent	111.10	131.90	70.40	120.00	198.90

Ratios

Valuation

12.73

1.56

10.19

4.18

63.89

521.65

Profitability

16.30

17.16

14.13

30.57

29.20

Leverage & Liquidity

0.08

3.01

41.62

Returns

0.61

0.48

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	49.71	49.62	49.62	49.56	49.56	49.48	49.48	49.42	49.42
	25.31	24.26	23.51	22.97	21.16	19.96	20.54	22.82	22.60
	24.97	26.12	26.88	27.46	29.28	30.56	29.97	27.76	27.98
	50.29	50.38	50.38	50.44	50.44	50.52	50.52	50.58	50.58
No. of Shareholders	2,51,485	3,02,944	3,45,332	4,05,222	4,29,434	4,19,699	4,24,167	4,10,970	4,03,166

Corporate Actions

Showing: All

Date	Type	Details
2026-09-09	Ex Rights	Right Issue of Equity Shares Inter-alia considered and approved the following: 1. Issuance of fully paid up equity shares of the Company of face value of Rs.2 each ( Rights Equity Shares ) for an amount not exceeding Rs.1,300 crore (Rupees One Thousand and Three Hundred Crore only) by way of a rights issue to the eligible equity shareholders of the Company, as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ( SEBI ICDR Regulations ), subject to such regulatory and statutory approvals, as may be required under the applicable laws. 2. Constitution of the Fund-Raising Committee of the Board with the following members and delegation of such powers as may be necessary to give effect to the Rights Issue: i. Sri V.C. Nannapaneni, Chairman ii. Sri Rajeev Nannapaneni, Member iii. Sri P.S.R.K. Prasad, Member 3. The Draft Letter of Offer for the Rights Issue, in accordance with the provisions of the Companies Act, 2013, the SEBI (ICDR) Regulations and other applicable laws. 4. Update on the Scheme of Arrangement (Demerger): In continuation to its earlier intimation about the scheme of arrangement (Demerger) between Natco Pharma Limited (Demerged Company or Company) and Natco Crop Health Sciences Limited (Resulting Company) and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (Scheme or Scheme of Arrangement). The Scheme was submitted to the Stock Exchanges in accordance with the applicable provisions of Regulation 37 of the SEBI LODR Regulations read with the SEBI Scheme Circular and the Company has received the Observation Letter from both the stock exchanges. The Company has not filed the Scheme and related applications with the Hon ble National Company Law Tribunal. The fund raising by way of a Rights Issue proposed at the meeting of the board of directors held on September 09, 2026 is expected to result in change to the Company s capital structure and shareholding pattern and consequently would require necessary changes to the Scheme. Accordingly, the Board at its meeting held on September 09, 2026, has considered and decided to consequentially make necessary changes to the Scheme appropriately post completion of the Rights Issue with a view to, inter alia, maintain the share swap ratio in the revised Scheme the same as the one proposed in the Scheme in respect of which the Company has received the Observation Letters from the Stock Exchanges. The Company proposes to make appropriate filings of such revised Scheme with the Stock Exchanges post completion of the now proposed Rights Issue as aforesaid.
2026-09-09	Demerger	Right Issue of Equity Shares Inter-alia considered and approved the following: 1. Issuance of fully paid up equity shares of the Company of face value of Rs.2 each ( Rights Equity Shares ) for an amount not exceeding Rs.1,300 crore (Rupees One Thousand and Three Hundred Crore only) by way of a rights issue to the eligible equity shareholders of the Company, as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ( SEBI ICDR Regulations ), subject to such regulatory and statutory approvals, as may be required under the applicable laws. 2. Constitution of the Fund-Raising Committee of the Board with the following members and delegation of such powers as may be necessary to give effect to the Rights Issue: i. Sri V.C. Nannapaneni, Chairman ii. Sri Rajeev Nannapaneni, Member iii. Sri P.S.R.K. Prasad, Member 3. The Draft Letter of Offer for the Rights Issue, in accordance with the provisions of the Companies Act, 2013, the SEBI (ICDR) Regulations and other applicable laws. 4. Update on the Scheme of Arrangement (Demerger): In continuation to its earlier intimation about the scheme of arrangement (Demerger) between Natco Pharma Limited (Demerged Company or Company) and Natco Crop Health Sciences Limited (Resulting Company) and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (Scheme or Scheme of Arrangement). The Scheme was submitted to the Stock Exchanges in accordance with the applicable provisions of Regulation 37 of the SEBI LODR Regulations read with the SEBI Scheme Circular and the Company has received the Observation Letter from both the stock exchanges. The Company has not filed the Scheme and related applications with the Hon ble National Company Law Tribunal. The fund raising by way of a Rights Issue proposed at the meeting of the board of directors held on September 09, 2026 is expected to result in change to the Company s capital structure and shareholding pattern and consequently would require necessary changes to the Scheme. Accordingly, the Board at its meeting held on September 09, 2026, has considered and decided to consequentially make necessary changes to the Scheme appropriately post completion of the Rights Issue with a view to, inter alia, maintain the share swap ratio in the revised Scheme the same as the one proposed in the Scheme in respect of which the Company has received the Observation Letters from the Stock Exchanges. The Company proposes to make appropriate filings of such revised Scheme with the Stock Exchanges post completion of the now proposed Rights Issue as aforesaid.
2026-09-07	AGM

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)
2026-08-26	DURGA DEVI NANNAPANENI	Gift	Sell	50,000

Sector Overview

HealthcarePharmaceuticals & Drugs

Natco Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

11 members across the board and senior leadership

Chekuri Venkat Ramesh

Company Secretary & Compliance Officer

—

V C Nannapaneni

Chairman & Managing Director

₹7.60 Cr

Mar '26

Rajeev Nannapaneni

Vice Chairman & CEO

₹7.39 Cr

Mar '26

ADM Chavali